Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates.
about
Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients.Modulation of autophagy-like processes by tumor viruses.The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence.Clinical application of mTORi based immunosuppression for renal transplantation in India.Enhanced apoptosis in post-liver transplant hepatitis C: effects of virus and immunosuppressantsImmunomodulating therapy in liver transplantation: principles and practice.Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients.Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances.Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors.Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database.Virus-drug interactions--molecular insight into immunosuppression and HCV.Preliminary report of major surgery in liver transplant recipients receiving m-TOR inhibitors without therapeutic discontinuation.The impact of immunosuppressant therapy on the recurrence of hepatitis C post-liver transplantation.
P2860
Q34093760-3987045B-A9EC-4074-875F-FA5E49E346E6Q34168552-95A8C588-6319-4637-BD43-C6D12F844743Q37512255-0A6101DC-7BDD-423A-8689-40D5B3C6750EQ37639714-38AFD0F5-DA8D-4386-8BEA-F78E8326D934Q37929851-6FB270C1-0835-4586-8E3C-4189AD65662FQ38011694-43395CC8-7711-4693-BBA8-9BED04410AAEQ38040507-DBCCC291-E7FF-4B03-AE87-85A6180D58D4Q38061056-FFCAEC58-BC70-4BF5-902B-9A82D7DDD806Q38286355-E1A5BBDE-8096-466D-8889-4F8129E2409AQ38584289-935FE6BA-EFDE-4A66-B866-BA24871ECA4AQ38947867-7756B5B8-5930-4B6A-AC2B-9AA399486BBAQ41631814-8099C87E-C81A-457F-BEFB-C8B8E3B01D47Q45357318-2EC0C3FA-A1CC-45D3-8FE2-059C86286E4DQ45358300-768C836F-5FAF-4137-A910-59D0BD2594DDQ54335179-D06DB855-38BB-4723-BE19-4B5308697FD7Q55692477-8F81217B-9F16-4407-BF60-6AB21631C4F9
P2860
Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Sirolimus has a potential to i ...... e liver transplant candidates.
@en
Sirolimus has a potential to i ...... e liver transplant candidates.
@nl
type
label
Sirolimus has a potential to i ...... e liver transplant candidates.
@en
Sirolimus has a potential to i ...... e liver transplant candidates.
@nl
prefLabel
Sirolimus has a potential to i ...... e liver transplant candidates.
@en
Sirolimus has a potential to i ...... e liver transplant candidates.
@nl
P2093
P1476
Sirolimus has a potential to i ...... e liver transplant candidates.
@en
P2093
Astrid Fahrleitner-Pammer
Daniela Kniepeiss
Doris Wagner
Estrella Jakoby
Florian Iberer
Helmut Mueller
Karl-Heinz Tscheliessnigg
Philipp Stiegler
Silvia Schaffellner
P304
P356
10.1016/J.INTIMP.2010.05.006
P577
2010-05-17T00:00:00Z